GYRE GYRE THERAPEUTICS, INC.: institutional ownership and insider trading
59 funds reported holding $65.7M of GYRE THERAPEUTICS, INC. in their latest 13F filings; in Q2 2026 funds net bought $34.7M, with 11 new positions and 7 funds selling out; over the last 12 months insiders bought $0 and sold $953K on the open market; over its last four quarters it reported revenue of $116M and net income of −$25.7M.
GYRE revenue and earnings
- Quarter ended Jun 30, 2026: revenue $29.1M, net income −$14.3M, EPS -0.12
- Quarter ended Mar 31, 2026: revenue $22.5M, net income −$18.6M, EPS -0.10
- Quarter ended Dec 31, 2025: revenue $34.2M, net income $1.24M, EPS 0.02
- Quarter ended Sep 30, 2025: revenue $30.6M, net income $5.94M, EPS 0.03
Famous investors holding GYRE
- Izzy Englander (Millennium Management): $122K, 0.0% of the portfolio
Largest institutional holders of GYRE
- HSG Holding Ltd — $24.7M
- VANGUARD GROUP INC — $8.48M
- BlackRock, Inc. (BLK) — $6.55M
- Octagon Capital Advisors LP — $6.29M
- VANGUARD CAPITAL MANAGEMENT LLC — $5.78M
- GEODE CAPITAL MANAGEMENT, LLC — $3.51M
- STATE STREET CORP (STT, STT-PG) — $1.62M
- SBI Securities Co., Ltd. — $1.24M
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC — $1.21M
- NORTHERN TRUST CORP (NTRS, NTRSO) — $1.12M
Recent GYRE insider trades
- Jun 18, 2026: Ye Weiguo sold 11,000 shares ($68.7K)
- Jun 11, 2026: Ye Weiguo sold 2,800 shares ($17.3K)
- Jun 10, 2026: Ye Weiguo sold 20,918 shares ($129K)
- Jun 5, 2026: Ye Weiguo sold 34,976 shares ($219K)
5%+ owners
- GNI USA, Inc.: 69.1% (Schedule 13D/A, filed May 6, 2026)
- Ying Luo: 8.6% (Schedule 13D/A, filed May 6, 2026)
- Songjiang Ma: 6.3% (Schedule 13D/A, filed May 7, 2026)